News | September 26, 2011

Civco Motion Management Symposium Explores Micro, Macro Aspects

September 26, 2011 — Civco Medical Solutions is hosting a motion management symposium in conjunction with the American Society for Therapeutic Radiology and Oncology (ASTRO) 2011 conference. The symposium, "The Future of Motion Management from Micro to Macro," will be held Monday, Oct. 3, at the Gansevoort Hotel in Miami Beach.

Civco invites attendees to explore the evolution of motion management from a micro to macro perspective. Leading clinicians will begin on the micro (patient-specific) level through discussions involving stereotactic body radiation therapy (SBRT) immobilization and submillimeter robotic patient positioning. Then, macro (facility-wide) motion management will be discussed featuring radio frequency identification (RFID) tracking of patients & equipment and its impact on departmental workflow. Pre-registration is required.

Four featured presentations will be given. Geoffrey Dalbow, Civco chief technology officer, will outline the concepts of micro and macro motion management and provide introductions for the clinical leaders to follow.

  • Clinical Experience of the Body Pro-Lok for SBRT Patient Immobilization – Alonso Gutierrez, Ph.D., assistant professor of radiation oncology, School of Medicine at the University of Texas Health Science Center San Antonio (UTHSCSA)
  • Clinical Impact of kV-CBCT Imaging Guided 6-D Robotic Couch in Stereotactic Radiosurgery Program – Tim Williams, M.D., medical director, Lynn Cancer Institute, Boca Raton Regional Hospital and Charles Shang, director of medical physics, Lynn Cancer Center, Boca Raton Regional Hospital
  • Quality Improvement & the Future of RFID and UCSD – Todd Pawlicki, director of medical physics, department of radiation oncology, Moores Cancer Center

Civco personnel will be available throughout the event for product-specific questions. Products discussed during presentations include Body Pro-Lok for SBRT, Protura Robotic Patient Positioning System and RFSuite RFID Tracking and Verification System.

For more information: www.civco.com

Related Content

more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
Augmenix Announces First New Zealand Prostate Cancer Patient Treated with SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | June 28, 2017
Augmenix Inc. announced that the first patient in New Zealand has been treated with SpaceOAR hydrogel at the Kathleen...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Versa

Image courtesy of Elekta

News | Radiation Therapy | June 13, 2017
Radiation therapy (RT) using high-energy particles, like X-rays or electron beams, is a common and critical component...
News | Radiation Oncology | June 12, 2017
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Sponsored Content | Case Study | Radiation Therapy | June 08, 2017
Stereotactic body radiation therapy (SBRT) employs significantly higher per fraction radiation doses than conventional...
pediatric imaging
News | Radiation Oncology | June 08, 2017
In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that e
Overlay Init